AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.
Antidepressive Agents, Tricyclic
/ therapeutic use
Constipation
/ diagnosis
Gastrointestinal Agents
/ adverse effects
Humans
Irritable Bowel Syndrome
/ complications
Laxatives
/ therapeutic use
Lubiprostone
/ therapeutic use
Parasympatholytics
/ therapeutic use
Polyethylene Glycols
/ therapeutic use
Selective Serotonin Reuptake Inhibitors
/ therapeutic use
Antispasmodic
Irritable Bowel Syndrome
Linaclotide
Lubiprostone
Meta-Analysis
Plecanatide
Polyethylene Glycol
Quality of Life
Randomized Controlled Trial
Selective Serotonin Reuptake Inhibitor
Symptoms
Tegaserod
Tenapanor
Treatment
Tricyclic Antidepressant
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
entrez:
23
6
2022
pubmed:
24
6
2022
medline:
28
6
2022
Statut:
ppublish
Résumé
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction associated with significant disease burden. This American Gastroenterological Association guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS-C and is an update of a prior technical review and guideline. The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. The technical review panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and conducted an evidence review of the following agents: tenapanor, plecanatide, linaclotide, tegaserod, lubiprostone, polyethylene glycol laxatives, tricyclic antidepressants, selective serotonin reuptake inhibitors, and antispasmodics. The Guideline Panel reviewed the evidence and used the Evidence-to-Decision Framework to develop recommendations. The panel agreed on 9 recommendations for the management of patients with IBS-C. The panel made a strong recommendation for linaclotide (high certainty) and conditional recommendations for tenapanor, plecanatide, tegaserod, and lubiprostone (moderate certainty), polyethylene glycol laxatives, tricyclic antidepressants, and antispasmodics (low certainty). The panel made a conditional recommendation against the use of selective serotonin reuptake inhibitors (low certainty).
Sections du résumé
BACKGROUND & AIMS
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction associated with significant disease burden. This American Gastroenterological Association guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS-C and is an update of a prior technical review and guideline.
METHODS
The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. The technical review panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and conducted an evidence review of the following agents: tenapanor, plecanatide, linaclotide, tegaserod, lubiprostone, polyethylene glycol laxatives, tricyclic antidepressants, selective serotonin reuptake inhibitors, and antispasmodics. The Guideline Panel reviewed the evidence and used the Evidence-to-Decision Framework to develop recommendations.
CONCLUSIONS
The panel agreed on 9 recommendations for the management of patients with IBS-C. The panel made a strong recommendation for linaclotide (high certainty) and conditional recommendations for tenapanor, plecanatide, tegaserod, and lubiprostone (moderate certainty), polyethylene glycol laxatives, tricyclic antidepressants, and antispasmodics (low certainty). The panel made a conditional recommendation against the use of selective serotonin reuptake inhibitors (low certainty).
Identifiants
pubmed: 35738724
pii: S0016-5085(22)00390-0
doi: 10.1053/j.gastro.2022.04.016
pii:
doi:
Substances chimiques
Antidepressive Agents, Tricyclic
0
Gastrointestinal Agents
0
Laxatives
0
Parasympatholytics
0
Serotonin Uptake Inhibitors
0
Polyethylene Glycols
3WJQ0SDW1A
Lubiprostone
7662KG2R6K
Types de publication
Practice Guideline
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118-136Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.